Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.
Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.
Mayo Clin Proc. 2018 Oct;93(10):1488-1502. doi: 10.1016/j.mayocp.2018.05.026.
Global Strategy for the Diagnosis, Management, and Prevention of COPD 2018 is a consensus report published periodically since 2001 by an international panel of health professionals from respiratory medicine, socioeconomics, public health, and education comprising the Global Initiative for Chronic Obstructive Lung Disease (GOLD). The GOLD documents endeavor to incorporate latest evidence and expert consensus and are intended for use as "strategy documents" for implementation of effective care for chronic obstructive lung disease (COPD) on a global level. The GOLD 2018 report defines COPD as a "common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities, usually caused by significant exposure to noxious particles or gases," with the criteria of "persistent respiratory symptoms" being a new and controversial inclusion since 2017. With the availability of newer pharmacotherapy options, treatment recommendations are made on the basis of a review of the latest literature and directed by symptom burden and health care utilization. Apart from the change in definition, a major shift in the recommendations is the exclusion of severity of airflow limitation as one of the major factors in guiding therapy. We review the salient features of the GOLD 2018 document and provide commentary on features that merit further discussion based on our clinical experience and practice as well as literature review current as of February 2018.
全球策略的诊断,管理,预防慢性阻塞性肺疾病 2018 年是一个共识报告定期出版自 2001 年以来由一个国际小组的健康专家从呼吸医学,社会经济学,公共卫生和教育包括全球倡议慢性阻塞性肺疾病(GOLD)。GOLD 文件努力纳入最新的证据和专家共识,并旨在作为“战略文件”为实施有效的护理慢性阻塞性肺疾病(COPD)在全球范围内。GOLD 2018 年报告定义为“常见的,可预防的和可治疗的疾病是由持续的呼吸道症状和气流受限,这是由于气道和/或肺泡异常,通常是由于大量接触有害颗粒或气体,”与“持续的呼吸道症状”的标准是新的和有争议的纳入自 2017 年以来。随着新型药物治疗选择的出现,根据最新文献的综述,并根据症状负担和医疗保健利用情况,提出了治疗建议。除了定义的改变外,建议的一个主要转变是将气流受限的严重程度排除为指导治疗的主要因素之一。我们审查了 GOLD 2018 年文件的主要特征,并根据我们的临床经验和实践以及截至 2018 年 2 月的文献综述提供了值得进一步讨论的特征的评论。